Alisa J Stephens-Shields1, Peter J Snyder2, Susan S Ellenberg1, Lynne Taylor1, Shalender Bhasin3,4. 1. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 2. Division of Endocrinology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 3. Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. 4. Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Abstract
CONTEXT: Many effects of testosterone are mediated through dihydrotestosterone (DHT) and estradiol. OBJECTIVE: To determine the relative contributions of each hormone to the observed effects of testosterone treatment in older men with hypogonadism. METHODS: Using data from the Testosterone Trials, we assessed the association of changes in total testosterone, estradiol, and DHT levels over 12 months of testosterone treatment with hemoglobin, high-density lipoprotein (HDL) cholesterol, volumetric bone mineral density (vBMD) of lumbar spine, sexual desire, and prostate-specific antigen (PSA). We used random forests to model the associations of predicted mean changes in outcomes with change in each hormone at low, mean, or high change in the other 2 hormones. Stepwise regression models were run to confirm the findings of random forests. RESULT: Predicted increases in hemoglobin and sexual desire were greater with larger increases in estradiol and were larger with high change in DHT compared with low change in DHT. Greater increases in estradiol were associated with larger decreases in HDL cholesterol; this association did not vary according to changes in DHT or testosterone. Change in vBMD was most robustly associated with change in estradiol and was greater with high change in testosterone and DHT. There was no consistent relation between change in PSA and change in any hormone. CONCLUSION: Change in estradiol level was the best predictor not only of the change in vBMD and sexual desire but also of the changes in hemoglobin and HDL cholesterol. Consideration of testosterone, estradiol, and DHT together offers a superior prediction of treatment response in older hypogonadal men than testosterone alone.
CONTEXT: Many effects of testosterone are mediated through dihydrotestosterone (DHT) and estradiol. OBJECTIVE: To determine the relative contributions of each hormone to the observed effects of testosterone treatment in older men with hypogonadism. METHODS: Using data from the Testosterone Trials, we assessed the association of changes in total testosterone, estradiol, and DHT levels over 12 months of testosterone treatment with hemoglobin, high-density lipoprotein (HDL) cholesterol, volumetric bone mineral density (vBMD) of lumbar spine, sexual desire, and prostate-specific antigen (PSA). We used random forests to model the associations of predicted mean changes in outcomes with change in each hormone at low, mean, or high change in the other 2 hormones. Stepwise regression models were run to confirm the findings of random forests. RESULT: Predicted increases in hemoglobin and sexual desire were greater with larger increases in estradiol and were larger with high change in DHT compared with low change in DHT. Greater increases in estradiol were associated with larger decreases in HDL cholesterol; this association did not vary according to changes in DHT or testosterone. Change in vBMD was most robustly associated with change in estradiol and was greater with high change in testosterone and DHT. There was no consistent relation between change in PSA and change in any hormone. CONCLUSION: Change in estradiol level was the best predictor not only of the change in vBMD and sexual desire but also of the changes in hemoglobin and HDL cholesterol. Consideration of testosterone, estradiol, and DHT together offers a superior prediction of treatment response in older hypogonadal men than testosterone alone.
Keywords:
dihydrotestosterone and bone mineral density; dihydrotestosterone and sexual desire; estradiol and HDL cholesterol; estradiol and hemoglobin; relation of sex hormones with outcomes; testosterone and bone mineral density; the testosterone trials
Authors: Emile R Mohler; Susan S Ellenberg; Cora E Lewis; Nanette K Wenger; Matthew J Budoff; Michael R Lewis; Elizabeth Barrett-Connor; Ronald S Swerdloff; Alisa Stephens-Shields; Shalender Bhasin; Jane A Cauley; Jill P Crandall; Glenn R Cunningham; Kristine E Ensrud; Thomas M Gill; Alvin M Matsumoto; Mark E Molitch; Marco Pahor; Peter E Preston; Xiaoling Hou; Denise Cifelli; Peter J Snyder Journal: J Clin Endocrinol Metab Date: 2018-02-01 Impact factor: 5.958
Authors: R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Shalender Bhasin; Juan P Brito; Glenn R Cunningham; Frances J Hayes; Howard N Hodis; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Frederick C Wu; Maria A Yialamas Journal: J Clin Endocrinol Metab Date: 2018-05-01 Impact factor: 5.958
Authors: Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson Journal: Endocr Rev Date: 2014-09-09 Impact factor: 19.871
Authors: S Kousteni; J R Chen; T Bellido; L Han; A A Ali; C A O'Brien; L Plotkin; Q Fu; A T Mancino; Y Wen; A M Vertino; C C Powers; S A Stewart; R Ebert; A M Parfitt; R S Weinstein; R L Jilka; S C Manolagas Journal: Science Date: 2002-10-25 Impact factor: 47.728